Haemonetics Corp (HAE) 37.48 $HAE Uptrend Call
Post# of 273254
Posted On: 09/24/2016 3:16:13 PM
Haemonetics Corp (HAE) 37.48 $HAE
Uptrend Call Working As Haemonetics Stock Rises 25.1% (HAE)
Comtex SmarTrend(R) - Wed Sep 21, 1:32PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 4 months, Haemonetics has returned 25.10% as of today's recent price of $36.63.
HAE: 37.48 (-0.20)
29.1% Return Seen to Date on SmarTrend Haemonetics Call (HAE)
Comtex SmarTrend(R) - Tue Sep 06, 1:38PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 3 months, Haemonetics has returned 29.11% as of today's recent price of $37.81.
HAE: 37.48 (-0.20)
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on Monday, September 12, 2016 at 1:40pm Eastern time.
HAE: 37.48 (-0.20), MS: 31.91 (-0.33)
Haemonetics to Present at The Baird 2016 Global Healthcare Conference
PR Newswire - Mon Aug 29, 3:15PM CDT
Haemonetics Corporation (NYSE:HAE) announced that Gerry Gould, Vice President - Investor Relations, will present at The Baird 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 3:10pm Eastern time.
HAE: 37.48 (-0.20)
Shares of HAE Up 23.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 26, 1:41PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 3 months, Haemonetics has returned 23.17% as of today's recent price of $36.07.
HAE: 37.48 (-0.20)
Haemonetics Shares Up 21.9% Since SmarTrend's Buy Recommendation (HAE)
Comtex SmarTrend(R) - Fri Aug 19, 1:19AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 2 months, Haemonetics has returned 21.94% as of today's recent price of $35.71.
HAE: 37.48 (-0.20)
Downgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue Aug 16, 3:06AM CDT
Haemonetics (NYSE:HAE) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $35.75 on volume of 416,000 shares, above average daily volume of 408,000. Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. The Company's products are for use in surgical blood salvage, blood component collections, and plasma collections. Haemonetics markets its products worldwide, primarily outside the United States.
HAE: 37.48 (-0.20)
Haemonetics CEO Completes Open Market Share Purchase
PR Newswire - Mon Aug 08, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of $35.00. The acquisition of these shares was by open market purchases taking place during the last three business days.
HAE: 37.48 (-0.20)
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 43.99 (-0.39), MASI: 59.77 (-0.55), HAE: 37.48 (-0.20), CPHD: 52.50 (unch)
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 37.48 (-0.20), NUVA: 66.77 (-1.29)
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.
HAE: 37.48 (-0.20)
Haemonetics Appoints Bill Burke CFO
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
HAE: 37.48 (-0.20)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 23.71 (-0.02), HAE: 37.48 (-0.20), BAX: 47.49 (-0.71), LMAT: 20.19 (-0.39)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
PR Newswire - Wed Jun 01, 7:00AM CDT
Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.
HAE: 37.48 (-0.20)
Haemonetics to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.
HAE: 37.48 (-0.20)
Uptrend Call Working As Haemonetics Stock Rises 25.1% (HAE)
Comtex SmarTrend(R) - Wed Sep 21, 1:32PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 4 months, Haemonetics has returned 25.10% as of today's recent price of $36.63.
HAE: 37.48 (-0.20)
29.1% Return Seen to Date on SmarTrend Haemonetics Call (HAE)
Comtex SmarTrend(R) - Tue Sep 06, 1:38PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 3 months, Haemonetics has returned 29.11% as of today's recent price of $37.81.
HAE: 37.48 (-0.20)
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on Monday, September 12, 2016 at 1:40pm Eastern time.
HAE: 37.48 (-0.20), MS: 31.91 (-0.33)
Haemonetics to Present at The Baird 2016 Global Healthcare Conference
PR Newswire - Mon Aug 29, 3:15PM CDT
Haemonetics Corporation (NYSE:HAE) announced that Gerry Gould, Vice President - Investor Relations, will present at The Baird 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 3:10pm Eastern time.
HAE: 37.48 (-0.20)
Shares of HAE Up 23.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 26, 1:41PM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 3 months, Haemonetics has returned 23.17% as of today's recent price of $36.07.
HAE: 37.48 (-0.20)
Haemonetics Shares Up 21.9% Since SmarTrend's Buy Recommendation (HAE)
Comtex SmarTrend(R) - Fri Aug 19, 1:19AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on June 8th, 2016 at $29.29. In approximately 2 months, Haemonetics has returned 21.94% as of today's recent price of $35.71.
HAE: 37.48 (-0.20)
Downgrade Alert for Haemonetics (HAE)
Comtex SmarTrend(R) - Tue Aug 16, 3:06AM CDT
Haemonetics (NYSE:HAE) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $35.75 on volume of 416,000 shares, above average daily volume of 408,000. Haemonetics Corporation designs, manufactures, and markets automated blood processing systems. The Company's products are for use in surgical blood salvage, blood component collections, and plasma collections. Haemonetics markets its products worldwide, primarily outside the United States.
HAE: 37.48 (-0.20)
Haemonetics CEO Completes Open Market Share Purchase
PR Newswire - Mon Aug 08, 3:01PM CDT
Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of $35.00. The acquisition of these shares was by open market purchases taking place during the last three business days.
HAE: 37.48 (-0.20)
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 43.99 (-0.39), MASI: 59.77 (-0.55), HAE: 37.48 (-0.20), CPHD: 52.50 (unch)
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 37.48 (-0.20), NUVA: 66.77 (-1.29)
Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.
HAE: 37.48 (-0.20)
Haemonetics Appoints Bill Burke CFO
PR Newswire - Mon Aug 01, 5:00AM CDT
Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
HAE: 37.48 (-0.20)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 23.71 (-0.02), HAE: 37.48 (-0.20), BAX: 47.49 (-0.71), LMAT: 20.19 (-0.39)
Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
PR Newswire - Wed Jun 01, 7:00AM CDT
Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category.
HAE: 37.48 (-0.20)
Haemonetics to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.
HAE: 37.48 (-0.20)
(0)
(0)Scroll down for more posts ▼